HER2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?

ConclusionMandatory repeat HER2 testing of grade 3 HER2 negative carcinomas is not appropriate. This is particularly true if repeat testing is performed after borderline negative amplification in the core or in HER2 negative heterogeneous carcinomas.This article is protected by copyright. All rights reserved.

Source: Histopathology - November 1, 2015 Category: Pathology Authors: Emad A Rakha, Marian Pigera, Sandra J Shin, Timothy D'Alfonso, Ian O Ellis, Andrew H S Lee Tags: Original Article Source Type: research